enicepatide vs Tirzepatide (Zepbound)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
enicepatide
Developed by Roche and partners
NCT06525935 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
Reported efficacy
Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)
Result source: NCT06525935
Tirzepatide (Zepbound)
Marketed by Eli Lilly
NCT04184622 · Phase 3 · completed
SURMOUNT-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes. Participants received weekly tirzepatide 5 mg, 10 mg or 15 mg or placebo for 72 weeks. The co-primary endpoints were the percent change in body weight and the share of participants who lost 5% or more of their weight. In the intention-to-treat analysis, weight fell by 15.0%, 19.5% and 20.9% with the three doses against 3.1% with placebo, and 85% to 91% of tirzepatide participants lost at least 5% against 35% with placebo (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.
Next expected readout: November 2026 · NCT07299084 (registry estimate)
Reported efficacy
Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21) (met)
Result source: NCT05412004
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | enicepatide | Tirzepatide (Zepbound) |
|---|---|---|
| Body weight, % change | —Trial running · NCT07670416 | -22.5% vs -2.4%−20.1 vs placeboNCT0418462220 other results
|
| Weight loss of 5% or more | —Trial running · NCT07670416 | 96.3% vs 27.9%+68.4 vs placeboNCT0418462212 other results
|
| Weight loss of 10% or more | —Trial running · NCT07670416 | 90.1% vs 13.5%+76.5 vs placeboNCT0418462210 other results
|
| Waist circumference, change (cm) | —Trial running · NCT07670416 | -19.9 vs -3.4−16.5 vs placeboNCT0418462212 other results
|
Body weight, % change
- enicepatide
- —Trial running · NCT07670416
- Tirzepatide (Zepbound)
- -22.5% vs -2.4%−20.1 vs placeboNCT04184622
20 other results
- -15.7% vs -3.3% NCT04657003
- -21.4% vs -2.4% NCT04184622
- -13.4% vs -3.3% NCT04657003
- -16% vs -2.4% NCT04184622
- -6.7% vs 14.8% NCT04660643
- -21.1% vs 3.3% NCT04657016
- -22.7% vs -1.7% NCT04844918
- -19.9% vs -2.4% NCT05024032
- -17.8% vs -1.7% NCT04844918
- -14.4% vs -2.4% NCT05024032
- -20.2% vs -13.7% NCT05822830
- -22.9% vs -2.1% NCT04184622
- -19.9% vs -2.1% NCT04184622
- -15.4% vs -2.1% NCT04184622
- -26% vs -9.5% NCT04660643
- -6% vs 9.9% NCT04660643
- -17.6% vs -2.3% NCT05412004
- -19.6% vs -2.3% NCT05412004
- -13.8% vs -2.2% NCT04847557
- -21.8% vs -15.4% NCT05822830
Weight loss of 5% or more
- enicepatide
- —Trial running · NCT07670416
- Tirzepatide (Zepbound)
- 96.3% vs 27.9%+68.4 vs placeboNCT04184622
12 other results
- 86.4% vs 30.6% NCT04657003
- 96.2% vs 27.9% NCT04184622
- 81.5% vs 30.6% NCT04657003
- 89.4% vs 27.9% NCT04184622
- 94.4% vs 10.7% NCT04657016
- 96.0% vs 20% NCT04844918
- 92.7% vs 29.4% NCT05024032
- 94.4% vs 20% NCT04844918
- 91.4% vs 29.4% NCT05024032
- 94.8% vs 24.6% NCT04184622
- 91.9% vs 24.6% NCT04184622
- 90.6% vs 24.6% NCT04184622
Weight loss of 10% or more
- enicepatide
- —Trial running · NCT07670416
- Tirzepatide (Zepbound)
- 90.1% vs 13.5%+76.5 vs placeboNCT04184622
10 other results
- 69.6% vs 8.7% NCT04657003
- 85.8% vs 13.5% NCT04184622
- 63.4% vs 8.7% NCT04657003
- 73.3% vs 13.5% NCT04184622
- 88.0% vs 4.8% NCT04657016
- 92.1% vs 4% NCT04844918
- 83.8% vs 14.7% NCT05024032
- 85.9% vs 4% NCT04844918
- 70% vs 14.7% NCT05024032
- 87.7% vs 66.7% NCT05822830
Waist circumference, change (cm)
- enicepatide
- —Trial running · NCT07670416
- Tirzepatide (Zepbound)
- -19.9 vs -3.4−16.5 vs placeboNCT04184622
12 other results
- -13.8 vs -3.4 NCT04657003
- -19.4 vs -3.4 NCT04184622
- -11.2 vs -3.4 NCT04657003
- -14.6 vs -3.4 NCT04184622
- -4.6 vs 8.3 NCT04660643
- -22.8 vs -9.1 NCT04660643
- -16.8 vs 1.1 NCT04657016
- -16.6 vs -1.3 NCT04844918
- -16.4 vs -2.7 NCT05024032
- -12.7 vs -1.3 NCT04844918
- -11.9 vs -2.7 NCT05024032
- -18.4 vs -13 NCT05822830
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. enicepatide: 0 of 4 rows · Tirzepatide (Zepbound): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tirzepatide (Zepbound) |
|---|---|
| Dropout rate | 8.7%15 mga NCT04184622 · Phase 3 show 19 more results11%10 mg NCT04184622 · Phase 3 9.7%5 mg NCT04184622 · Phase 3 9.3%15 mg NCT04657003 · Phase 3 —10 mg NCT04657003 · Phase 3 12.2% NCT04657016 · Phase 3 —MTD NCT04660643 · Phase 3 11.4%MTD NCT05412004 · Phase 3 5.8%MTD NCT05412004 · Phase 3 14.9%15 mg or MTD NCT05822830 · Phase 3 · registry result, not featured evidence 8.8%MTD NCT04847557 · Phase 3 · registry result, not featured evidence 27.8%15 mg NCT04844918 · Phase 3 · registry result, not featured evidence —10 mg NCT04844918 · Phase 3 · registry result, not featured evidence 5.6%15 mg NCT05024032 · Phase 3 · registry result, not featured evidence —10 mg NCT05024032 · Phase 3 · registry result, not featured evidence 16.7%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 14.3%1.25-2.5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 14.3%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 16.2% NCT04311411 · Phase 1 · registry result, not featured evidence —15 mg NCT04081337 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 1%15 mga NCT04184622 · Phase 3 show 19 more results1.3%10 mg NCT04184622 · Phase 3 0.6%5 mg NCT04184622 · Phase 3 1.6%15 mg NCT04657003 · Phase 3 —10 mg NCT04657003 · Phase 3 1.4% NCT04657016 · Phase 3 —MTD NCT04660643 · Phase 3 0%MTD NCT05412004 · Phase 3 0.8%MTD NCT05412004 · Phase 3 1.6%15 mg or MTD NCT05822830 · Phase 3 · registry result, not featured evidence 0.3%MTD NCT04847557 · Phase 3 · registry result, not featured evidence 8.9%15 mg NCT04844918 · Phase 3 · registry result, not featured evidence —10 mg NCT04844918 · Phase 3 · registry result, not featured evidence 1.4%15 mg NCT05024032 · Phase 3 · registry result, not featured evidence —10 mg NCT05024032 · Phase 3 · registry result, not featured evidence 0%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 0%1.25-2.5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 14.3%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 8.1% NCT04311411 · Phase 1 · registry result, not featured evidence —15 mg NCT04081337 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 7.9%15 mga NCT04184622 · Phase 3 show 19 more results9.4%10 mg NCT04184622 · Phase 3 9%5 mg NCT04184622 · Phase 3 8.7%15 mg NCT04657003 · Phase 3 5.8%10 mg NCT04657003 · Phase 3 5.9% NCT04657016 · Phase 3 3%MTD NCT04660643 · Phase 3 7.9%MTD NCT05412004 · Phase 3 5.9%MTD NCT05412004 · Phase 3 4.8%15 mg or MTD NCT05822830 · Phase 3 · registry result, not featured evidence 26.4%MTD NCT04847557 · Phase 3 · registry result, not featured evidence 6.5%15 mg NCT04844918 · Phase 3 · registry result, not featured evidence 11%10 mg NCT04844918 · Phase 3 · registry result, not featured evidence 11.3%15 mg NCT05024032 · Phase 3 · registry result, not featured evidence 4.3%10 mg NCT05024032 · Phase 3 · registry result, not featured evidence 0%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 0%1.25-2.5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 0%2.5-5 mg NCT05696847 · Phase 1 · registry result, not featured evidence 0% NCT04311411 · Phase 1 · registry result, not featured evidence 3.7%15 mg NCT04081337 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 15 mga nausea 31.9% (placebo 9.8%) diarrhoea 23.7% (placebo 7.9%) covid-19 17.9% (placebo 16.5%) NCT04184622 · Phase 3 show 19 more results10 mg nausea 34.1% (placebo 9.8%) diarrhoea 22.5% (placebo 7.9%) covid-19 20.1% (placebo 16.5%) NCT04184622 · Phase 3 5 mg nausea 25.4% (placebo 9.8%) diarrhoea 20.3% (placebo 7.9%) covid-19 20.2% (placebo 16.5%) NCT04184622 · Phase 3 15 mg nausea 21.9% (placebo 6.3%) diarrhoea 21.2% (placebo 8.9%) vomiting 12.9% (placebo 3.2%) NCT04657003 · Phase 3 10 mg nausea 20.2% (placebo 6.3%) diarrhoea 19.9% (placebo 8.9%) covid-19 16.7% (placebo 16.8%) NCT04657003 · Phase 3 nausea 39.7% (placebo 14%) diarrhoea 31% (placebo 9.2%) constipation 23% (placebo 6.8%) NCT04657016 · Phase 3 MTD covid-19 14% (placebo 14.9%) diarrhoea 10.7% (placebo 4.8%) nausea 8.1% (placebo 2.7%) NCT04660643 · Phase 3 MTD diarrhoea 26.3% (placebo 12.5%) nausea 25.4% (placebo 10%) vomiting 17.5% (placebo 4.2%) NCT05412004 · Phase 3 MTD diarrhoea 21.8% (placebo 12.5%) nausea 21.8% (placebo 10%) constipation 15.1% (placebo 2.5%) NCT05412004 · Phase 3 15 mg or MTD nausea 43.6% constipation 27% diarrhoea 23.5% NCT05822830 · Phase 3 · registry result, not featured evidence MTD diarrhoea 17.9% (placebo 6.3%) nausea 17% (placebo 6.3%) constipation 14.8% (placebo 6%) NCT04847557 · Phase 3 · registry result, not featured evidence 15 mg constipation 27.3% (placebo 6.7%) nausea 23.4% (placebo 4%) covid-19 19.5% (placebo 17.3%) NCT04844918 · Phase 3 · registry result, not featured evidence 10 mg covid-19 20.5% (placebo 17.3%) constipation 16.4% (placebo 6.7%) nausea 13.7% (placebo 4%) NCT04844918 · Phase 3 · registry result, not featured evidence 15 mg diarrhoea 40.8% (placebo 8.7%) nausea 32.4% (placebo 5.8%) decreased appetite 28.2% (placebo 11.6%) NCT05024032 · Phase 3 · registry result, not featured evidence 10 mg diarrhoea 40% (placebo 8.7%) nausea 30% (placebo 5.8%) decreased appetite 27.1% (placebo 11.6%) NCT05024032 · Phase 3 · registry result, not featured evidence 2.5-5 mg decreased appetite 50% (placebo 0%) nausea 50% (placebo 0%) constipation 33.3% (placebo 0%) NCT05696847 · Phase 1 · registry result, not featured evidence 1.25-2.5 mg nausea 28.6% (placebo 0%) abdominal pain 14.3% (placebo 0%) cough 14.3% (placebo 0%) NCT05696847 · Phase 1 · registry result, not featured evidence 2.5-5 mg vomiting 85.7% (placebo 0%) nausea 71.4% (placebo 0%) abdominal pain 57.1% (placebo 0%) NCT05696847 · Phase 1 · registry result, not featured evidence nausea 51.4% (placebo 5.1%) vomiting 29.7% (placebo 2.6%) constipation 18.9% (placebo 0%) NCT04311411 · Phase 1 · registry result, not featured evidence 15 mg nausea 51.9% (placebo 25%) constipation 37% (placebo 14.3%) injection site reaction 37% (placebo 0%) NCT04081337 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tirzepatide (Zepbound)
show 20 more results
show 12 more results
show 10 more results
show 10 more results
show 6 more results
show 12 more results
show 12 more results
show 12 more results
show 8 more results
show 11 more results
show 11 more results
show 1 more result
+ 56 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · Tirzepatide (Zepbound)'s landscape